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ABSTRACT
Equilibrium and kinetic in vitro potassium ions (potassium chloride) binding studies were used
to document bioequivalence between generic (T) and innovator (R) formulations of the cationic
exchange resin, sodium polystyrene sulfonate (SPS) that is used in the treatment of hyperkalemia.
The equilibrium binding studies were conducted under identical experimental conditions of
constant time, and varying concentrations of potassium chloride in either simulated intestinal fluid
(SIF) or water, with and without acid pretreatment of the drug product. The kinetic binding studies
were conducted under constant concentrations of potassium chloride (0.3 and 3 mM) in either
water or SIF with varying times of observation. Flame photometric technique was used to measure
the concentration of non-bound potassium ions. Equilibrium binding studies of potassium ions to
SPS in simulated intestinal fluid (SIF) did not follow Langmuir-type adsorption isotherm,
otherwise, equilibrium binding studies in water have shown to obey Langmuir equation with
correlation coefficient (R2) of 0.972 for both formulations. The calculated affinity (k1) and capacity
(k2) binding constants were found to be (1.41; 1.25) and (3.1; 3.55 mMole/g) for generic and
innovator formulations, respectively. The T/R ratios for total potassium ions bound ranged from
0.85 to 1.01 at 0.1 – 30 mM concentrations. The T/R ratios for both affinity and capacity constants
were 1.13 and 0.87 respectively. In kinetic binding studies, both drug products have exhibited the
same rate of exchange for potassium ions. Therefore, based on both equilibrium and kinetic data
the two drug products were comparable in terms of their in vitro binding characteristics.
Keywords: In Vitro Bioequivalence, Potassium Binding Resins, Sodium Polystyrene
Sulfonate.
polystyrene sulfonate (SPS) is a cationINTRODUCTION
exchange resin prepared in the sodium form
Bioequivalence (BE) studies are required
and has the structure shown in Figure (1)
by regulatory authorities to ensure clinical
CH2CH2
safety and efficacy of drug products.
However, this may be unsuitable for orally
administered drugs intended for local action
and not reaching the systemic circulation,
documentation of bioavailability (BA) and
bioequivalence (BE) can be achieved by
suitably designed in-vitro studies (1).
Ion exchange materials are insoluble
substances that contain loosely held ions
exchangeable with other ions in solutions
coming in contact with them. They can
exchange either positively charged ions
(cation exchangers) or negatively charged
ones (anion exchangers). These exchanges
take place without any physical alteration to
the ion exchange material (2). Sodium

SO3-Na+

Figure (1): Chemical Structure of SPS.
SPS has been previously used to get rid
of toxicity of different cations like lithium
and iron (3) (4). Recently, SPS, either taken
orally or by enema, has been used for the
treatment of hyperkalemia, by exchanging its
Na+ with K+ in the large intestine (5). In fact,
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each gram of SPS exchanges usually not less
than 110 mg and not more than 135 mg of
K+, calculated on the anhydrous basis (6). As
a requirement for registration, the Division of
Bioequivalence at the Food and Drug
Administration (FDA) has concluded that in
vivo studies are not necessary to document
the BE of a generic drug product in case of
Cholestyramine resin formulations, since this
drug shows low water solubility and
intestinal permeability (7). Accordingly, in
vitro BE studies including both equilibrium
and kinetic studies were sufficient to confirm
the BE between the generic and brand
formulations (7). Despite SPS is rated “AA”
in the FDA/CDER’s Approved Drug
Products with therapeutic Equivalence
Evaluation where no known or specified
bioequivalence issue is known or suspected,
the information necessary to show
bioequivalence between pharmaceutically
equivalent products is presumed and
considered self-evident based on acceptable
in vitro studies that ensure the absence of
effect for factors that can affect the exchange
process in comparison with brand products
(10) like the particle size. Following the
same principles outlined above for the in
vitro BE testing of Cholestyramine, in vitro
testing of SPS can be used to in lieu of in
vivo testing.
To the best of our knowledge, there is no
published report on the in vitro approach to
evaluate the in vitro equivalence between the
generic SPS and the brand product.
Accordingly, this work would be of great
importance to the pharmaceutical industry
and academic research that wish to develop
new generic formulations and obtain
preliminary prediction about the in vivo
performance of the obtained formulation. In
this study, both binding and equilibrium for
SPS were carried out in order to compare the
In vitro binding characteristics between the
generic (Pharmacin-S®) and the innovator
(Kayexalate®) formulations (in vitro BE
studies).
MATERIALS AND METHODS
Materials
powder
(Jerusalem
Pharmacin-S®
Pharmaceuticals,
Ramallah,
Palestine),
Kayexalate® powder (Sanofi Aventis -

France), monobasic sodium phosphate
(Merck-Germany),
sodium
hydroxide
(Merck-Germany), KCl (Merck-Germany),
sodium
chloride
(Merck-Germany),
hydrochloric acid (Merck-Germany), sodium
hydroxide (Merck-Germany).
Methods
The simulated intestinal fluid (SIF) was
prepared to contain 0.05 M sodium
phosphate buffer solution with pH 6.8
without enzymes. Standard solutions of KCl
with concentrations covering the range of
0.05 -1.5 mM were prepared. These
concentrations were analyzed using flame
photometer. To obtain standard curves, signal
versus K+ concentration plots were
constructed. For equilibrium binding studies,
50 mg of SPS powder of either Pharmacin-S®
or Kayexalate® were soaked in 10 mL of
either SIF or water overnight at room
temperature
with
or
without
acid
pretreatment. The acid pretreated samples
were previously soaked in 10 ml of 0.1 N
HCl at 37°C for 1 hour. Then, the pH of the
sample solutions was adjusted to 6.8 with 1
N NaOH then allowed to soak overnight at
room temperature. In the day after, different
concentrations of KCl (0.1 - 30 mM)
solutions were prepared by adding the
specified volumes of 100 mM KCl stock
solution and complete the remaining volume
with SIF or water. The samples were
incubated at 37 °C for 24 hours. Then they
were filtered, diluted and analyzed by means
of flame photometer. All experiments were
conducted as six replicates as per the FDA
guidance on Cholestyramine (7).
For kinetic binding studies, 50 mg of
SPS powder of either Pharmacin-S® or
Kayexalate® were soaked in 10 ml of
distilled water at room temperature
overnight. Then, the volume of 100 mM KCl
solution required to obtain a potassium
concentration of 0.3 and 3 mM was added
quickly and the volume was completed to 50
ml by water. The samples were incubated at
37 °C and samples were withdrawn at
different time intervals (0.25, 0.5, 1, 2, 4, 8,
16, and 24 hours), filtered, diluted and
analyzed by flame photometer. All
experiments were conducted as six replicates.
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solution at equilibrium, x is the amount of
adsorbate bound to the adsorbent (SPS), m is
the amount of adsorbent used, k1 is the
affinity constant, k2 is capacity constant
which is account for the maximum amount of
adsorbate that can be adsorbed per unit
weight of adsorbent.

Calculation of adsorption equilibrium and
kinetic parameters:
For SPS, the ion exchange process is an
equilibrium process that can be explained by
the following reaction:
SPS-Na+ + K+ ↔ SPS-K+ + Na+
Usually the exchange depends on factors
such as: (i) the concentration of both Na+ and
K+, (ii) the affinity of resin with these ions,
and (iii) the number of reactive sites (i.e., the
binding capacity) in the matrix. As proposed
by Langmuir regarding the adsorption of
gases on plane surfaces, the monomolecular
adsorption of potassium ions from solution
can be described by the following equation
(8):

Based on that, different types of
adsorption isotherms have been proposed (8).
In order for adsorption to follow Langmuir
type, the adsorption isotherm should show
saturable adsorption as the concentration of
the adsorbate increases.
RESULTS
Standard curves of K+ have shown
linearity over the concentration range of
0.05-1.5 mM K+ with correlation coefficient
of 0.998 and 0.997 in SIF and water
respectively. The standard curve of K+ in
water is shown in Figure 3.

Ceq
1
Ceq


x / m k1k2 K 2
Where Ceq represents the concentration
of the adsorbate (K+) remaining in the
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Figure (3): Standard curve of K+ in water
Regarding the equilibrium binding studies in SIF, plots of micromoles K+ bound /50 mg resin
versus initial concentration of K+ were constructed as in Figure 4. The plots do not follow
Langmuir type isotherm, thus Langmuir equation was not applicable in this case. The same results
were obtained with samples that were previously acid treated.
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Figure (4): Micromoles potassium bound /50 mg SPS versus initial potassium concentration (mM)
for Pharmacin-S in SIF without acid pretreatment.
obtained for both Pharmacin-S® and
Kayexalate® in water without acid
pretreatment can be observed.

Concerning the equilibrium binding studies
in water, Figure 5 has shown to follow
Langmuir
equation
with
monolayer
adsorption. In fact, the monolayer isotherms
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Figure (5): Micromoles bound of K per 50 mg resin versus the initial potassium concentration
(mM) for (a) Pharmacin-S ® and (b) Kayexalate ® in water without acid pretreatment. To apply
Langmuir equation, the required parameters were calculated as in Table 1.
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Table (1): Summary of calculations required to apply Langmuir equation for equilibrium studies
in water without acid pretreatment for both formulations

Plots of Ceq /x/m versus Ceq were
constructed as shown in Figure 6 and
Langmuir parameters were calculated for
both formulations as shown in Table 2. Both

formulations have shown to follow Langmuir
type adsorption with good correlation. It is
obvious that deviation from Langmuir
equation occurs at high concentrations.
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Figure (6): Langmuir Plots for both formulations (a) Kayexalate® (b) Pharmacin-S® for the
equilibrium study in water without acid pretreatment.
Table 2 shows Langmuir parameters along with the results for the Statistical Analysis of the
ratios using SPSS program.
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Table (2): Langmuir Isotherm parameters with statistical analysis
Drug Product
Affinity constant (k1)
Capacity (k2) [mmol/g]
Correlation Coefficient (r2)

Pharmasin
Reference/Test
S®
Kayexalate®
Ratio (R/T)
1.41
1.25
0.92
3.1
3.55
1.14
0.972
0.972
------

No difference was obtained in
experiments done with acid pretreatment.
The binding of K+ to SPS at the two initial K+
concentrations: 0.3 mM and 3.0 mM was

90% Confidence
Interval
0.802-1.05
1.12-1.17
------

extremely rapid (equilibrium was achieved
within 15 minutes) and identical for both
drug products. The results for the kinetic
studies are shown in Figure 7.
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Figure (7): Kinetic studies for Pharmacin-S® and Kayexalate® for the equilibrium study in water
without acid pretreatment.
DISCUSSION
A conventional human pharmacokinetic
in vivo study is often considered the "gold
standard" to determine bioequivalence of
drug products. However, this BE approach is
not always applicable to products not
intended to be delivered into the systemic
circulation. Examples of these drugs are the
antihyperlipidimic resins Cholestyramine,
phosphate binding drugs, potassium binding
agents among others (9). In these situations,
the FDA has proposed in vitro binding
studies as an alternative approach for the in
vivo studies. The FDA did not provide
guidance for Kayexalate® specifically, but a
guidance was given for Cholestyramine (7).
The protocol suggested for Cholestyramine
was used as the starting point to establish our
own method of analysis to determine the
equivalence between Kayexalate® and

Pharmacin®. The protocol suggested both
equilibrium and kinetic experiments in order
to assess both the extent and rate of release of
the active ingredient from the dosage form in
its intended site of action (i.e., the small
intestines).
A validated analytical method for
potassium based on flame photometric
technique was established to assess K+
concentrations upon incubation with the
binding resin under different experimental
conditions. The equilibrium studies in SIF
have not obeyed type I isotherm but a Type II
was obtained. Accordingly, Langmuir
equation was not applicable. This may be due
to the presence of high Na+ concentrations in
SIF that may compete for the adsorption of
K+. This can be ensured by the adsorption
isotherm obtained in water in which no Na+
was found. These studies obeyed Langmuir
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isotherm and the parameters needed to
evaluate the BE between the reference and
test products were calculated. Application of
Langmuir equation on both drug products
was satisfactory with good correlation.
Statistical Analysis using SPSS program
reveals that the Reference/Test ratios for
affinity and capacity constants are acceptable
with a 90% confidence interval that lies
within the acceptance criteria stated by FDA
guidelines (80% - 125%) regarding the
bioequivalence.

Based on the kinetic and equilibrium
binding studies the both drug products
and
Kayexalate®
are
Pharmacin-S®
comparable in terms of their in vitro binding
characteristics.
Accordingly,
their
interchangeability could be practiced.
However, further post-marketing surveillance
must be conducted in order to assess any
relevant issue regarding their safety and
efficacy among patients.
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